ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026)
ArriVent BioPharma (AVBP) posted Income from Continuing Operations of 83371000.0 for Q1 2026, down 133.45% sequentially from 35712000.0 in Q4 2025, and up 11.22% YoY from 74957515.36 in Q1 2025.
ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Income from Continuing Operations for 4 years, with the latest figure at 83371000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 11.22% year-over-year to 83371000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 250951000.0 (down 7.46% YoY) and the FY2025 annual result came in at 197983000.0, down 51.32% from the prior year.
- Income from Continuing Operations slipped to 83371000.0 in Q1 2026 per AVBP's latest filing, from 35712000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 12172000.0 in Q1 2023 and troughed at 93912000.0 in Q1 2025.
- A 4-year average of 49871000.0 and a median of 55003000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 67.55% in 2024, down 340.46% in 2024.
- Over 4 years, Income from Continuing Operations stood at 65315000.0 in 2023, then jumped by 67.55% to 21194000.0 in 2024, then plunged by 68.5% to 35712000.0 in 2025, then slumped by 133.45% to 83371000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 83371000.0, 35712000.0, and 63453000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -164.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -164.99 Mn |
| Mar 31, 2026 | -83.37 Mn |
| Dec 31, 2025 | -35.71 Mn |
| Sep 30, 2025 | -63.45 Mn |
| Jun 30, 2025 | -68.42 Mn |
| Mar 31, 2025 | -93.91 Mn |
| Dec 31, 2024 | -21.19 Mn |
| Sep 30, 2024 | -63.43 Mn |
| Jun 30, 2024 | -55.00 Mn |
| Mar 31, 2024 | -50.38 Mn |
| Dec 31, 2023 | -65.32 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -21.57 Mn |
| Mar 31, 2023 | -12.17 Mn |